**Anne B. Curtis, MD, FACC**
SUNY Distinguished Professor of Medicine Emeritus
University of Buffalo

**Printed as of 10/30/2026**

# Disclosures

## Personal Commercial (4)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| *Self* | | | |
| Abbott | Consultant Fees/Honoraria | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Janssen Pharmaceuticals, Inc | Consultant Fees/Honoraria | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Medtronic | Consultant Fees/Honoraria | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |
| Sanofi Aventis | Consultant Fees/Honoraria | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| *Self* | | | |
| American College of Cardiology | Consultant Fees/Honoraria | Modest (< $5,000) | *Arrhythmias and Clinical EP* |
| Medscape | Consultant Fees/Honoraria | Significant (>= $5,000) | *Arrhythmias and Clinical EP* |

## Clinical Trial Enroller (2)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|---|---|
| REACT-AF | National Institutes of Health | National Institutes of Health |
| RECOVER | National Institutes of Health | |

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|---|---|---|---|---|
| *Self* | | | | |
| 2024 | Failure to implant an ICD | Defendant<br>*† Sandberg Phoenix* | Woman in her 30's died suddenly. Previous holter showed artifact that was correctly recognized. Plaintiff asserts that rhythm was actually polymorphic VT and should have led to implantation of an ICD. | Significant (>= $5,000) |

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

## Certified Education Attestation | Signed on 9/4/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

## Confidentiality, Disclosure and Assignment Agreement | Signed on 9/4/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

## Embargo | Signed on 9/4/2026
*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

## On-Going Obligation Agreement | Signed on 9/4/2026

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.